Disc Medicine, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Disc Medicine, Inc. (IRON) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.06 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-26
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 100.14K shares, a 81.22% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 99.61K shares, a 56.17% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-06-30 was 79.66K shares, a 13.13% decline year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 616.87K shares, a 2295.06% increase year-over-year.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.06M shares, a 18.32% increase from fiscal 2024.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 896.27K shares, a 278.97% increase from fiscal 2023.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 236.50K shares, a 75.83% decline from fiscal 2022.
- Disc Medicine, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 978.54K shares, a 80.65% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 1.06M shares 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 100.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 199.74K shares derived: sum of 2 quarters · filed 2025-02-27 | 279.40K shares derived: sum of 3 quarters · filed 2025-02-27 | 896.27K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 99.61K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 179.27K shares derived: sum of 2 quarters · filed 2024-11-12 | 796.14K shares 10-Q · filed 2024-11-12 | 851.40K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 79.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 696.53K shares 10-Q · filed 2024-08-08 | 751.79K shares derived: sum of 3 quarters · filed 2024-08-08 | 815.57K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 616.87K shares 10-Q · filed 2024-05-09 | 672.13K shares derived: sum of 2 quarters · filed 2024-05-09 | 735.91K shares derived: sum of 3 quarters · filed 2024-05-09 | 827.62K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 55.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 119.04K shares derived: sum of 2 quarters · filed 2024-03-21 | 210.75K shares derived: sum of 3 quarters · filed 2024-03-21 | 236.50K shares 10-K · filed 2024-03-21 |
| 2023-09-30 | 63.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 155.49K shares derived: sum of 2 quarters · filed 2023-11-09 | 181.25K shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 91.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 117.46K shares 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | 25.76K shares 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 978.54K shares 10-K · filed 2023-03-31 | |||
| 2021-12-31 | 5.06M shares 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |